Increased serum matrix metalloproteinase-9 in neuromyelitis optica: Implication of disruption of blood-brain barrier

Journal of Neuroimmunology

Volumn 236, Issue 1-2, 2011, Pages 81-86

  Hosokawa, Takafumi ^a   Nakajima, Hideto ^a,b   Doi, Yoshimitsu ^a   Sugino, Masakazu ^a   Kimura, Fumiharu ^a   Hanafusa, Toshiaki ^a   Takahashi, Toshiyuki ^c  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Seikeikai Hospital   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti aquaporin 4 antibody; Blood brain barrier; IL 8; MMP 9; Multiple sclerosis; Neuromyelitis optica

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; IMMUNOGLOBULIN G; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM ALBUMIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MATRIX METALLOPROTEINASE 9 BLOOD LEVEL; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEUROMYELITIS OPTICA; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT;

EID: 79960172701     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.04.009     Document Type: Article

References (40)

1. Avolio C., Ruggieri M., Giuliani F., Liuzzi G.M., Leante R., Riccio P., Livrea P., Trojano M. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J. Neuroimmunol. 2003, 136:46-53.
2. Baggiolini M., Dewald B., Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv. Immunol. 1994, 55:97-179.
3. Benesova Y., Vasku A., Novotna H., Litzman J., Stourac P., Beranek M., Kadanka Z., Bednarik J. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult. Scler. 2009, 15:316-322.
4. Bradl M., Misu T., Takahashi T., Watanabe M., Mader S., Reindl M., Adzemovic M., Bauer J., Berger T., Fujihara K., Itoyama Y., Lassmann H. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 2009, 66:630-643.
5. Clements J.M., Cossins J.A., Wells G.M., Corkill D.J., Helfrich K., Wood L.M., Pigott R., Stabler G., Ward G.A., Gearing A.J., Miller K.M. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J. Neuroimmunol. 1997, 74:85-94.
6. Goetzl E.J., Banda M.J., Leppert D. Matrix metalloproteinases in immunity. J. Immunol. 1996, 156:1-4.
7. Ishizu T., Osoegawa M., Mei F.J., Kikuchi H., Tanaka M., Takakura Y., Minohara M., Murai H., Mihara F., Taniwaki T., Kira J. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005, 128:988-1002.
8. Kieseier B.C., Paul R., Koedel U., Seifert T., Clements J.M., Gearing A.J., Pfister H.W., Hartung H.P. Differential expression of matrix metalloproteinases in bacterial meningitis. Brain 1999, 122(Pt 8):1579-1587.
9. Kinoshita M., Nakatsuji Y., Moriya M., Okuno T., Kumanogoh A., Nakano M., Takahashi T., Fujihara K., Tanaka K., Sakoda S. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 2009, 20:508-512.
10. Kolb S.A., Lahrtz F., Paul R., Leppert D., Nadal D., Pfister H.W., Fontana A. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J. Neuroimmunol. 1998, 84:143-150.
11. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
12. Lacraz S., Nicod L.P., Chicheportiche R., Welgus H.G., Dayer J.M. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest. 1995, 96:2304-2310.
13. Lassmann H., Stemberger H., Kitz K., Wisniewski H.M. In vivo demyelinating activity of sera from animals with chronic experimental allergic encephalomyelitis. Antibody nature of the demyelinating factor and the role of complement. J. Neurol. Sci. 1983, 59:123-137002E.
14. Lee M.A., Palace J., Stabler G., Ford J., Gearing A., Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999, 122(Pt 2):191-197.
15. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
16. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202:473-477.
17. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S., Miller K.M., Hauser S.L., Kappos L. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998, 121(Pt 12):2327-2334.
18. Liuzzi G.M., Trojano M., Fanelli M., Avolio C., Fasano A., Livrea P., Riccio P. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult. Scler. 2002, 8:222-228.
19. Lukes A., Mun-Bryce S., Lukes M., Rosenberg G.A. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol. Neurobiol. 1999, 19:267-284.
20. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990, 6:121-125.
21. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
22. Misu T., Fujihara K., Kakita A., Konno H., Nakamura M., Watanabe S., Takahashi T., Nakashima I., Takahashi H., Itoyama Y. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007, 130:1224-1234.
23. Muroski M.E., Roycik M.D., Newcomer R.G., Van den Steen P.E., Opdenakker G., Monroe H.R., Sahab Z.J., Sang Q.X. Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr. Pharm. Biotechnol. 2008, 9:34-46.
24. Murphy G., Knauper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?. Matrix Biol. 1997, 15:511-518.
25. Nakashima I., Fujihara K., Fujimori J., Narikawa K., Misu T., Itoyama Y. Absence of IgG1 response in the cerebrospinal fluid of relapsing neuromyelitis optica. Neurology 2004, 62:144-146.
26. Nicchia G.P., Nico B., Camassa L.M., Mola M.G., Loh N., Dermietzel R., Spray D.C., Svelto M., Frigeri A. The role of aquaporin-4 in the blood-brain barrier development and integrity: studies in animal and cell culture models. Neuroscience 2004, 129:935-945.
27. Nishiyama S., Ito T., Misu T., Takahashi T., Kikuchi A., Suzuki N., Jin K., Aoki M., Fujihara K., Itoyama Y. A case of NMO seropositive for aquaporin-4 antibody more than 10years before onset. Neurology 2009, 72:1960-1961.
28. Opdenakker G., Van den Steen P.E., Dubois B., Nelissen I., Van Coillie E., Masure S., Proost P., Van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol. 2001, 69:851-859.
29. Piddlesden S.J., Lassmann H., Zimprich F., Morgan B.P., Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am. J. Pathol. 1993, 143:555-564.
30. Pugin J., Widmer M.C., Kossodo S., Liang C.M., Preas H.L.n., Suffredini A.F. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am. J. Respir. Cell Mol. Biol. 1999, 20:458-464.
31. Rubin L.L., Staddon J.M. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 1999, 22:11-28.
32. Sopata I., Wize J., Filipowicz-Sosnowska A., Stanislawska-Biernat E., Brzezinska B., Maslinski S. Neutrophil gelatinase levels in plasma and synovial fluid of patients with rheumatic diseases. Rheumatol. Int. 1995, 15:9-14.
33. Takahashi T., Fujihara K., Nakashima I., Misu T., Miyazawa I., Nakamura M., Watanabe S., Ishii N., Itoyama Y. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J. Exp. Med. 2006, 210:307-313.
34. Takahashi T., Fujihara K., Nakashima I., Misu T., Miyazawa I., Nakamura M., Watanabe S., Shiga Y., Kanaoka C., Fujimori J., Sato S., Itoyama Y. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007, 130:1235-1243.
35. Vass K., Heininger K., Schafer B., Linington C., Lassmann H. Interferon-gamma potentiates antibody-mediated demyelination in vivo. Ann. Neurol. 1992, 32:198-206.
36. Watanabe S., Nakashima I., Misu T., Miyazawa I., Shiga Y., Fujihara K., Itoyama Y. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult. Scler. 2007, 13:128-132.
37. Waters P., Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int. MS J. 2008, 15:99-105.
38. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
39. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6:805-815.
40. Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2001, 2:502-511.